Ami Organics Ltd
NSE:AMIORG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (16.4), the stock would be worth ₹930.49 (30% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 23.4 | ₹1 327.4 |
0%
|
| 3-Year Average | 16.4 | ₹930.49 |
-30%
|
| 5-Year Average | 7.7 | ₹437.86 |
-67%
|
| Industry Average | 6.5 | ₹372.02 |
-72%
|
| Country Average | 6.5 | ₹372.02 |
-72%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Ami Organics Ltd
NSE:AMIORG
|
108.7B INR | 23.4 | 68.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 17.4 | 44.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 8.8 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 6.3 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 6.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 7.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 5.9 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 160.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 5.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 4.2 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 4.3 | 16.7 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 4.1 |
| Median | 6.5 |
| 70th Percentile | 10.8 |
| Max | 34 392.2 |
Other Multiples
Ami Organics Ltd
Glance View
Ami Organics Ltd. engages in the development and commercialization of pharmaceutical intermediate products. The company is headquartered in Surat, Gujarat and currently employs 561 full-time employees. The company went IPO on 2021-09-14. These specialty chemicals with varied end usage, focus on the development and manufacturing of pharma intermediates for regulated and generic active pharmaceutical ingredient (APIs) and new chemical entity (NCEs). The company manufactures pharma intermediates for certain APIs, including dolutegravir, trazodone, entacapone, nintedanib and rivaroxaban. The pharma intermediates, which the Company manufactures have application in certain high-growth therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant and anti-coagulant. The company has developed and commercialized over 450 pharma intermediates for APIs and NCEs across 17 therapeutic areas. Its specialty chemicals have applications in the agrochemicals and fine chemicals industries. The firm supplies its products to more than 150 customers directly in India.
